{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:36:32Z","timestamp":1786120592091,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"DOI":"10.7759\/cureus.114081","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:11:20Z","timestamp":1786061480000},"source":"Crossref","is-referenced-by-count":0,"title":["When Tapering Is Not an Option: Transitioning From High-Dose Methadone to Buprenorphine"],"prefix":"10.7759","author":[{"given":"Sarah","family":"Petelinsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarom","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Zaugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Coudreaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Methadose [package insert]. Food and Drug Administration. (2025). Accessed. June 12, 2026: https:\/\/www.accessdata.fda.gov."},{"key":"ref2","unstructured":"Methadone hydrochloride [package insert]. Food and Drug Administration. (2025). Accessed. June 12, 2026: https:\/\/www.accessdata.fda.gov."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.51337","article-title":"Population-level health benefits and harms associated with buprenorphine\/naloxone vs methadone","volume":"8","author":"Enns B","year":"2025","unstructured":"Enns B, Guerra-Alejos BC, Min JE, Carter A, Siebert U, Nosyk B. Population-level health benefits and harms associated with buprenorphine\/naloxone vs methadone. JAMA Netw Open. 2025, 8:e2551337. 10.1001\/jamanetworkopen.2025.51337","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder","volume":"332","author":"Nosyk B","year":"2024","unstructured":"Nosyk B, Min JE, Homayra F, et al.. Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder. J Am Med Assoc. 2024, 332:1822-31. 10.1001\/jama.2024.16954","journal-title":"J Am Med Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline","volume":"15","author":"Chou R","year":"2014","unstructured":"Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. J Pain. 2014, 15:338-65. 10.1016\/j.jpain.2014.01.495","journal-title":"J Pain"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.002","article-title":"Cardiovascular complications of opioid use: JACC state-of-the-art review","volume":"77","author":"Krantz MJ","year":"2021","unstructured":"Krantz MJ, Palmer RB, Haigney MC. Cardiovascular complications of opioid use: JACC state-of-the-art review. J Am Coll Cardiol. 2021, 77:205-23. 10.1016\/j.jacc.2020.11.002","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045304","article-title":"QTc prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT): a systematic review and meta-analysis","volume":"104","author":"Paknahad MH","year":"2025","unstructured":"Paknahad MH, Soleimani A, Baharlouei Yancheshmeh F, Adib-Hajbagheri P, Amerizadeh A, Karimi R. QTc prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT): a systematic review and meta-analysis. Medicine (Baltimore). 2025, 104:e45304. 10.1097\/MD.0000000000045304","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.23180008","article-title":"Treatment of opioid use disorder in the general hospital","author":"Funk MC","year":"2022","unstructured":"Funk MC, Nash S, Smith A, et al.. Treatment of opioid use disorder in the general hospital. Am J Psychiatry. 2022, 10.1176\/appi.ajp.23180008","journal-title":"Am J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.01.494","article-title":"Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society","volume":"15","author":"Chou R","year":"2014","unstructured":"Chou R, Cruciani RA, Fiellin DA, et al.. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014, 15:321-37. 10.1016\/j.jpain.2014.01.494","journal-title":"J Pain"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.8361","article-title":"Buprenorphine, pain, and opioid use in patients taking high-dose long-term opioids: a randomized clinical trial","volume":"185","author":"Becker WC","year":"2025","unstructured":"Becker WC, Seal KH, Nelson DB, et al.. Buprenorphine, pain, and opioid use in patients taking high-dose long-term opioids: a randomized clinical trial. JAMA Intern Med. 2025, 185:372-81. 10.1001\/jamainternmed.2024.8361","journal-title":"JAMA Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice Guideline for Prescribing Opioids for Pain - United States, 2022","volume":"71","author":"Dowell D","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022, 71:1-95. 10.15585\/mmwr.rr7103a1","journal-title":"MMWR Recomm Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.7282","article-title":"Caring for hospitalized adults with opioid use disorder in the era of fentanyl: a review","volume":"184","author":"Englander H","year":"2024","unstructured":"Englander H, Thakrar AP, Bagley SM, Rolley T, Dong K, Hyshka E. Caring for hospitalized adults with opioid use disorder in the era of fentanyl: a review. JAMA Intern Med. 2024, 184:691-701. 10.1001\/jamainternmed.2023.7282","journal-title":"JAMA Intern Med"},{"key":"ref13","article-title":"Transfer from methadone to buprenorphine","author":"Casadonte PP","year":"2024","unstructured":"Casadonte PP. Transfer from methadone to buprenorphine. Am J Addict. 2024,","journal-title":"Am J Addict"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/502601-when-tapering-is-not-an-option-transitioning-from-high-dose-methadone-to-buprenorphine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:11:22Z","timestamp":1786061482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/502601-when-tapering-is-not-an-option-transitioning-from-high-dose-methadone-to-buprenorphine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.114081","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}